PDF(Pubmed)
Abstract：
There is a high prevalence of heart failure (HF) worldwide, which has significant consequences for healthcare costs, patient death and quality of life. Therefore, there has been much focus on finding and using biomarkers for early diagnosis, prognostication and therapy of HF. This overview of the research presents a thorough examination of the current state of HF biomarkers and their many uses. Their function in diagnosing HF, gauging its severity and monitoring its response to therapy are all discussed. Particularly promising in HF diagnosis and risk stratification are the cardiac-specific biomarkers, B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide. Markers of oxidative stress, extracellular matrix, renal function, inflammation and cardiac peptides have shown promise in evaluating HF severity and prognosis. MicroRNAs and insulin-like growth factor are two emerging biomarkers that have shown potential in helping with HF diagnosis and prognosis.
摘要：
心力衰竭（HF）的患病率很高，这对医疗保健成本有重大影响，患者死亡和生活质量。因此,人们一直非常关注寻找和使用生物标志物进行早期诊断，HF的预后和治疗。这项研究的概述提供了对HF生物标志物的当前状态及其许多用途的全面检查。它们在诊断HF中的作用,衡量其严重程度和监测其对治疗的反应都进行了讨论。在HF诊断和危险分层中特别有希望的是心脏特异性生物标志物，B型利钠肽和N末端B型利钠肽前体。氧化应激标志物，细胞外基质，肾功能,炎症和心肌肽在评估HF严重程度和预后方面显示出希望。MicroRNAs和胰岛素样生长因子是两种新兴的生物标志物，显示出有助于HF诊断和预后的潜力。
